RPL29 and chronic myelogenous leukemia, BCR-ABL1 positive: The results demonstrated that overexpression of Rpl29 shortened survival (median survival: Vector vs Rpl29 was 29 vs 18 days), worsened the splenomegaly and spleen weight, and increased the leukemia burden as well as the percentages of LSPCs in BM and spleen of secondary CML mice (Figure S10O–W, Supporting Information).